Podcasts about lead article

Fluoride Free NZ Website - https://fluoridefree.org.nz Fluoride is the new Lead (Article) - https://fluoridefree.org.nz/fluoride-is-the-new-lead/ NZ Dentist Blows Whistle on Fluoridation - https://fluoridefree.org.nz/nz-dentist-blows-whistle-on-fluoridation/ Contact: mary@fluoridefree.org.nz Judges-Ruling-Fluoridation-is-an-Unreasonable-risk (download) - https://mega.nz/file/DdYFXTII#JdCrla9TH8ISmcP46I5AfoKIvLUHYqJw4fFWTZXDy4o Fluoride Report on Vigilant News https://x.com/VigilantFox/status/1840526671394566344  Good News for Humanity (Article) - https://drtenpenny.substack.com/p/good-news-for-humanity Fluoridation gives bottle-fed babies a huge dose – dose known to affect thyroid and IQ - https://fluoridefree.org.nz/fluoridation-gives-bottle-fed-babies-a-huge-dose-dose-known-to-affect-thyroid-and-iq/ Tauranga fluoride directive: City council denied extension, could face ‘extreme' penalties - https://www.nzherald.co.nz/bay-of-plenty-times/news/tauranga-fluoride-directive-city-council-denied-extension-could-face-extreme-penalties/ENS3PAB7HFD2NJGXJZYK5ZEK4E/

In this rebroadcasted episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Ainhoa Madariaga to discuss parp inhibitor treatments and adverse events. Dr. Madariaga's article "Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events" (ijgc.bmj.com/content/early/2020…8/ijgc-2020-001288), was the Lead Article in the July 2020 issue of IJGC. Dr. Madariaga is a medical oncologist working as a clinical research fellow in the gynecology and drug development program at Princess Margaret Cancer Centre. Her clinical and academic areas of interest are gynecologic cancers and early phase clinical trial design, such as development of drug-repurposing studies, cancer treatment adverse event and patient reported outcomes assessment. Original release date: July 6, 2021

In this rebroadcasted episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Kathleen Schmeler to discuss the ConCerv Trial. Dr. Schmeler is the lead author of “ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer,” which was the Lead Article of IJGC's October 2021 issue. Dr. Schmeler is a Professor in Gynecologic Oncology at The University of Texas MD Anderson Cancer Center. She provides care to women with gynecologic malignancies including surgery, chemotherapy and preventive services. Dr. Schmeler is also the Executive Director of Global Oncology for the MD Anderson Cancer Network. Her research interest is in cervical cancer prevention and treatment, particularly for resource-constrained countries and medically underserved communities in the US. Original release date: October 4, 2021 Highlights: - The ConCerv trial is the first prospective study of conservative surgery in women with low-risk cervical cancer. It included 14 sites in 9 countries. - Findings from the ConCerv Trial offer prospective data supporting a more conservative approach to low-risk patients, sparing them the early and late morbidity associated with radical procedures. - It will also allow for safer cervical cancer surgery in low- and middle-income countries, where the burden of cervical cancer is highest. - In our study, conservative surgery was associated with a 3.5% recurrence rate in women with low-risk cervical cancer. In addition, the rate of positive lymph nodes was 5%, with lymph node assessment recommended in this low-risk population. - Further study is needed to determine long term outcomes and optimal pathologic criteria for conservative surgery.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Andreina Fernandes to discuss HPV-independent Cervical Cancers. Dr. Fernandes is a Molecular Biologist, Doctor of Science, and author of “Human papillomavirus-independent cervical cancer,” the Lead Article for the January 2022 issue of IJGC. Dr. Fernandes is a Researcher of the Molecular Genetics Laboratory at the Institute of Oncology and Hematology, and Professor of the Faculty of Dentistry, at Universidad Central de Venezuela in Caracas, Venezuela. (https://ijgc.bmj.com/content/early/2021/12/08/ijgc-2021-003014) Highlights: -The percentage of HPV-independent tumors is very variable, around 5 and 10%. -HPV-independent tumors are characterized by a differentiated molecular profile with lower proliferative activity, a p53 immunostaining, and alterations in PTEN, p53, KRAS, CTNNB1, ARID1A and ARID5B. -Most HPV-independent tumors are adenocarcinomas, however, there have been reports of HPV-independent cases with squamous histology. -HPV-independent tumors are associated with early lymph node involvement, accelerated tumor growth, distant metastasis, and a more aggressive biological behavior, related to a worse disease free survival and overall survival. -The hit and run mechanism could explain the absence of the viral genome in the HPV-independent cervical cancer cases. Andreina Fernandes (@AndreFernandes2)

In this rebroadcasted episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Professor Christina Fotopoulou to discuss the ESGO Guidelines on Perioperative Management Ovarian Cancer. Professor Fotopoulou is the lead author of “European Society of Gynaecological Oncology guidelines for the peri-operative management of patients with ovarian cancer,” which is the Lead Article of IJGC's September 2021 issue. Professor Fotopoulou works at the Department of Surgery and Cancer at Imperial College London, UK. She is an elected ESGO council member and Chair of the ESGO guidelines committee.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Jennifer Chae-Kim. Dr. Chae-Kim is the author of Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis, which is the Lead Article of IJGC's December 2021 issue. Dr. Chae-Kim is in her last year of OB/GYN residency at BSW-Temple, and will be pursuing her interests in fertility preservation and fellowship training in REI at the NIH next year. https://ijgc.bmj.com/content/early/2021/11/15/ijgc-2021-002699 Jennifer Chae-Kim (@chae_md) Highlights 1) Endometrial cancer and atypical endometrial hyperplasia are being diagnosed more frequently in reproductive-aged women, who may desire fertility-sparing therapy. 2) Women who received progestin and metformin therapy were found to have lower disease relapse rates than those who received progestin alone. 3) Combined therapy was not associated with significantly different rates of disease remission, pregnancy, live birth. 4) Further research is needed to determine the parameters of clinical application of metformin to progestin therapy.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Drs. Katherina Grette and Nathaniel Jones to discuss racial inequities in immunotherapy trials and their article, “Not immune to inequity: minority under-representation in immunotherapy trials for breast and gynecologic cancers,” which is the Lead Article in IJGC's November 2021 issue. (https://ijgc.bmj.com/content/early/2021/09/21/ijgc-2021-002557) Dr. Katherine Grette attended medical school at the University of Washington, then completed her residency in Obstetrics and Gynecology at the University of South Alabama prior to joining faculty. She currently practices as a generalist and serves as the Assistant Director of Resident Research for the department. Dr. Nate Jones completed residency at Mountain Area Health Education Center in Asheville, NC followed by fellowship in Gynecologic Oncology at New York Presbyterian Hospitals: Columbia and Cornell. He currently serves as Assistant Professor in Gynecologic Oncology at the University of South Alabama Mitchell Cancer Institute. His research interests center on targeted cancer therapies, molecular and genomic characteristics of gynecologic malignancies, and addressing racial disparities in gynecologic cancer care. Highlights •Minority women are poorly represented in immunotherapy clinical trials for breast and gynecologic cancers •Enrollment of black women is especially low, accounting for only 5% of participants •Minority participation in clinical trials must increase to improve equity in health outcomes @natejones333 / @katgrette / @usamci

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Kathleen Schmeler to discuss the ConCerv Trial. Dr. Schmeler is the lead author of ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer, which is the Lead Article of IJGC's October 2021 issue. Dr. Schmeler is a Professor in Gynecologic Oncology at The University of Texas MD Anderson Cancer Center. She provides care to women with gynecologic malignancies including surgery, chemotherapy and preventive services. Dr. Schmeler is also the Executive Director of Global Oncology for the MD Anderson Cancer Network. Her research interest is in cervical cancer prevention and treatment, particularly for resource-constrained countries and medically underserved communities in the US. ( https://ijgc.bmj.com/content/early/2021/09/06/ijgc-2021-002921.share ) @kmschmeler @MDAndersonNews Highlights: •The ConCerv trial is the first prospective study of conservative surgery in women with low-risk cervical cancer. It included 14 sites in 9 countries. •Findings from the ConCerv Trial offer prospective data supporting a more conservative approach to low-risk patients, sparing them the early and late morbidity associated with radical procedures. •It will also allow for safer cervical cancer surgery in low- and middle-income countries, where the burden of cervical cancer is highest. •In the our study, conservative surgery was associated with a 3.5% recurrence rate in women with low-risk cervical cancer. In addition, the rate of positive lymph nodes was 5%, with lymph node assessment recommended in this low-risk population. •Further study is needed to determine long term outcomes and optimal pathologic criteria for conservative surgery."

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Professor Christina Fotopoulou to discuss the ESGO Guidelines on Perioperative Management Ovarian Cancer. Professor Fotopoulou is the lead author of “European Society of Gynaecological Oncology guidelines for the peri-operative management of patients with ovarian cancer,” which is the Lead Article of IJGC's September 2021 issue. Professor Fotopoulou works at the Department of Surgery and Cancer at Imperial College London, UK. She is an elected ESGO council member and Chair of the ESGO guidelines committee. Highlights - Patients with advanced ovarian cancer need to have a holistic care assessment and detailed discussion about risks and benefits of surgical treatment tailored to their individual profile. - A multidisciplinary team approach and complications management is crucial for the safe delivery of cytoreductive procedures - Maximal infrastructural expertise and specialization are keys to surgical success Christina Fotopoulou (@CF_PC_OvCaGroup)

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Dimitrios Nasioudis to discuss minimally invasive surgery in stage IA cervical cancer and his article, "Minimally invasive hysterectomy for stage IA cervical carcinoma: a survival analysis of the National Cancer Database," which is the Lead Article in the August 2021 issue of IJGC. Dr. Nasioudis is a resident at the Hospital of the University of Pennsylvania, Philadelphia. His current interests include population science and outcomes research with an emphasis on rare gynecologic tumors. Dimitrios Nasioudis (@Dnasioudis / @PennMedicine)

Andrew Clamp (@TheChristieNHS and @OfficialUoM) In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Andrew Clamp to discuss rucaparib maintenance in recurrent ovarian cancer (ARIEL3). Dr. Clamp is an author of “Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3,” the Lead Article for IJGC's July 2021 issue. Dr. Clamp is a Consultant and Honorary Senior Lecturer in Medical Oncology subspecializing in the treatment of gynaecological cancers. He is Chief Investigator for the MRC ICON8 Trials Programme and leads the gynaecological cancers clinical research team at The Christie. Highlights - Rucaparib provides a clinically significant prolongation of progression-free survival when used as maintenance treatment for platinum-sensitive recurrent ovarian cancer. - In the ARIEL3 trial, rucaparib extended progression-free survival versus placebo regardless of the length of the penultimate platinum-free interval, number of prior chemotherapy regimens or previous use of bevacizumab. - After extended follow-up, rucaparib was well-tolerated and its safety profile was not impacted by prior treatment history. - Maintenance PARP inhibitors should be considered for all PARP inhibitor naïve patients with recurrent high grade ovarian cancer after response to platinum-based chemotherapy.

(@K8SLN_MDMBA / @MLiangMD / @BIDMC_ObGyn / @UABOGYN / @ONealCancerUAB) In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Drs. Katharine Esselen and Margaret Liang to discuss financial toxicity in gynecologic cancers and their article, “Evaluating meaningful levels of financial toxicity in gynecologic cancers,” which is the Lead Article of IJGC's June 2021 issue. Dr. Esselen, MD, MBA, is a gynecologic oncologist at Beth Israel Deaconess Medical Center and Assistant Professor of Obstetrics, Gynecology and Reproductive Biology at Harvard Medical School in Boston, MA. She is the Associate Fellowship Program Director and Director of Clinical Research for the Division of Gynecologic Oncology. Dr. Liang, MD, MS, is a gynecologic oncologist and health services researcher at University of Alabama at Birmingham and O'Neal Comprehensive Cancer Center. She is Network Relations Lead for the newly established Emotional Well-being and Economic Burden Research Network (EMOT-ECON). Highlights - ~50% of gynecologic cancer patients report financial toxicity and ~15% experience severe financial toxicity - Patients with severe financial toxicity are 4.6 times more likely to report medication non-compliance - More work needs to be done to understand the impact of financial toxicity on clinical outcomes including adherence to treatment and cancer survival - Proposed interventions include development of screening tools, provider training in cost conversations, enhanced financial navigation, insurance optimization, improved workplace leave policies, and value-based care healthcare models"

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Andreas Obermair to discuss SLN mapping in endometrial cancer consensus with Andreas Obermair. Dr. Obermair is the lead author on , “Development of a surgical competency assessment tool for sentinel lymph node dissection by minimally invasive surgery for endometrial cancer” (https://ijgc.bmj.com/content/early/2021/03/31/ijgc-2020-002315), which is the Lead Article for the May 2021 issue of IJGC. Dr. Obermair is a gynaecological oncologist in Brisbane, Australia promoting surgery with proven better patient outcomes.

In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Dr. Michael Frumovitz to discuss radical hysterectomy in cervical neuroendocrine carcinoma. Dr. Frumovitz is an Associate Editor for IJGC and the author of the Lead Article of the April 2021 issue of IJGC, “Role of radical hysterectomy in patients with early-stage high-grade neuroendocrine cervical carcinoma: a NeCTuR study" (https://ijgc.bmj.com/content/early/2021/03/09/ijgc-2020-002213). Highlights: 1. Patients with clinical and radiologic stage I high grade neuroendocrine carcinoma of the cervix will have microscopic parametrial involvement 10% of the time 2. All patients with parametrial involvement will have other risk factors requiring postoperative radiation (positive nodes or Sedlis) 3. If a patient has negative nodes, the risk of parametrial involvement is only 3% 4. Eighty percent of recurrences will happen within first two years and 86% destined to recur will recur within 3 years

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Mona El-Bahrawyto discuss ovarian sex cord stromal tumors. Dr. El-Bahrawy is the lead author of “Ovarian sex cord-stromal tumors: an update on clinical features, molecular changes, and management" (https://ijgc.bmj.com/content/early/2021/01/07/ijgc-2020-002018), which is the Lead Article of IJGC’s February 2021 issue. Dr. El-Bahrawy is Professor of Practice in Histopathology at Imperial College London, United Kingdom, and Professor of Pathology at the University of Alexandria, Egypt, and President of the Egyptian Committee for Pathology Training. She specializes in Gynaecological Surgical Pathology with special interest in Gynaecological Tumour Pathology. Highlights: - Ovarian sex cord stromal tumours are rare tumours that include benign and malignant variants. - They are broadly classified into three categories, which include pure stromal tumors, pure sex cord tumors and mixed sex cord stromal tumors. - Some tumor types harbor hallmark mutations, such as FOXL-2 mutations detected in the majority of adult granulosa cell tumors. - Surgery is the main treatment modality for sex cord stromal tumors with some role for chemotherapy and hormonal therapy in advanced and recurrent tumors. - There is potential for the identification of therapeutic targets and development of targeted therapy for these tumors.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Carlos Martinez-Gomez to discuss TOPIC. Dr. Martinez-Gomez is an author of the Lead Article for IJGC’s January 2021 issue, “Urinary diversion after pelvic exenteration for gynecologic malignancies” (https://ijgc.bmj.com/content/early/2020/11/22/ijgc-2020-002015). Dr. Martinez-Gomez is a gynecologist oncologist at Institut Universitaire du Cancer de Toulouse, France, from 2016, where he performed the ESGO fellowship program under the supervision of Drs. Gwénaël Ferron and Alejandra Martinez. His areas of interest are immunology of cervical and ovarian neoplasms, advanced ovarian cancer, reconstructive surgery after pelvic exenteration, and surgical teaching. Highlights: • Pelvic exenteration is a demanding surgery requiring mastery of organ removal combined with functional reconstruction • Pelvic exenteration should be performed in high-volume referral institutions by well-trained multidisciplinary teams • Incontinent diversion represents a good option for unfit patients or those refusing the constraints entailed by continent diversions (self-catheterization, postoperative learning, engagement) • Postoperative complications of both types of reconstruction are comparable, but the quality of life issues would seem to support continent diversions in young and fit patients • Continent and non-contingent techniques should be offered to patients, with a final decision based on their preferences

In this rebroadcasted episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Dimitrios Nasioudis a to discuss adjuvant treatment in UPSC limited to endometrium and his article, "Adjuvant treatment for patients with FIGO stage I uterine serous carcinoma confined to the endometrium," (ijgc.bmj.com/content/early/2020…4/ijgc-2020-001379) the Lead Article in the August 2020 issue of IJGC. Dr. Nasioudis is a resident at the Hospital of the University of Pennsylvania, Philadelphia. His current interests include population science and outcomes research with an emphasis on rare gynecologic tumors.

In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Dr. Simone Marnitz-Schulze and Dr. Christhardt Köhler to discuss the outcomes of UTERUS-11 Trial. Drs. Marnitz-Schulze and Köhler are authors of “Surgical versus Clinical Staging prior to primary Chemoradiation in Patients with Cervical Cancer FIGO Stages IIB-IVA: Oncologic Results of a Prospective Randomized International Multicentre (Uterus-11) Intergroup Study,” which is the Lead Article of the December 2020 issue of the International Journal of Gynecological Cancer. Highlights: -Surgical staging prior to chemoradiation in locally advanced cervical cancer is safe, feasible, does not delay chemoradiation -Lead to an upstaging in 33% of the patients -Resulted into a statistically significant improvement of DFS in FIGO stage IIB patients -Resulted into a trend for improved OS and DFS for all subgroups -Because of high rates of distant metastases, systemic treatment has to be intensified

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Anna Fagotti to discuss the results of the SCORPION trial. Dr. Fagotti is the lead author of "Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)", which is the Lead Article of IJGC’s November 2020 issue (https://ijgc.bmj.com/content/early/2020/10/07/ijgc-2020-001640). Dr. Fagotti is the Ovarian Cancer Unit Director at Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome, Italy, as well as an Associate Professor of Obstetrics and Gynecology at Università Cattolica del Sacro Cuore. Additionally, she is PhD Faculty of Biotechnology at University of Perugia, ESGO Council Member and Chair of the Educational Committee, as well as an Associate Editor for IJGC. Highlights: 1. PDS and NACT ± IDS have superimposable median PFS and OS in patients with HTL ovarian cancer. 2. PDS has a higher rate of postoperative complications than IDS. 3. RT is the most powerful prognostic factor in AOC patients both at PDS and IDS"

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Drs. Gregg Nelson and Geetu Bhandoria to discuss the ERAS Global Survey. Their article, "Enhanced Recovery After Surgery (ERAS) in gynecologic oncology: an international survey of peri-operative practice” (https://ijgc.bmj.com/content/early/2020/08/28/ijgc-2020-001683), is the Lead Article in the October 2020 of IJGC. Dr. Gregg Nelson is Professor and Chief of Gynecologic Oncology at the Tom Baker Cancer Centre in Calgary, Alberta, Canada. His main research interest is the development and study of Enhanced Recovery After Surgery (ERAS) protocols in cancer and ObGyn surgery. Dr. Nelson is Secretary of the ERAS Society. Dr. Geetu Bhandoria is a Gynecologic Oncologist and obstetrician at Command Hospital in Pune, India. He as completed fellowship in Gynecologic Oncology. His research interests are advanced ovarian cancer, enhanced recovery protocols and the use of social media as a research tool. He is also currently serving as one of IJGC’s Editorial Fellows.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Luis Chiva to discuss the SUCCOR Study and his article, “SUCCOR study: an international European cohort observational study comparing minimally invasive surgery versus open abdominal radical hysterectomy in patients with stage IB1 cervical cancer” (https://ijgc.bmj.com/content/early/2020/08/18/ijgc-2020-001506), which is the Lead Article in the September 2020 issue of IJGC. Dr. Luis Chiva is the Director of the Department of Obstetrics and Gynecology at Clinica Universidad de Navarra. He is also the Video Editor of IJGC, Editor-in-Chief of E-academy and Chair of Quality Assurance & Certifications Committee at European Society of Gynecological Oncology.

In Episode 2 of Behind the Science of Career Development, APCDJ Editor and Global Career Guy Brian Hutchison hosts Yvonne Kong-Ho and Jeremiah Wong to learn the story of their article from the September 2019 Lead Article titled It Takes a Village: Meet the Singapore Career Development Tribe. This wide ranging conversation covered several topics of interest for career practitioners in Singapore and around the world, including  Career practice over the lifespan, from childhood to post retirement. Collaboration between school, university, union, government, and private sector career constituents. Collectivist culture and career development planning. Women in the workforce and career development. The process of academic publishing for first timers. The history of career development in Singapore - players and personalities. Asia Pacific Career Development Journal:  https://AsiaPacificCDA.org/Journal (https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fasiapacificcda.org%2FJournal&data=02%7C01%7C%7Caa083b42fffa4188496d08d83e274339%7C84df9e7fe9f640afb435aaaaaaaaaaaa%7C1%7C0%7C637327685630960316&sdata=tjqUEzUfVg6Te6CveocqfQNX8R3ijyy0jkM8%2F7zA6%2Fk%3D&reserved=0) Join APCDA: https://AsiaPacificCDA.org/Join-Renew (https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fasiapacificcda.org%2FJoin-Renew&data=02%7C01%7C%7Caa083b42fffa4188496d08d83e274339%7C84df9e7fe9f640afb435aaaaaaaaaaaa%7C1%7C0%7C637327685630970315&sdata=cLyYCBTnOZ9Mk4ZqF1BChdreIEtR%2Bjx6odJQbYpi6QM%3D&reserved=0) Attend a monthly webinar on global career issues:  https://AsiaPacificCDA /Webinars   Follow Brian Hutchison on Twitter @globalcareerguy

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Dimitrios Nasioudis a to discuss adjuvant treatment in UPSC limited to endometrium and his article, "Adjuvant treatment for patients with FIGO stage I uterine serous carcinoma confined to the endometrium," (https://ijgc.bmj.com/content/early/2020/07/14/ijgc-2020-001379) which is the Lead Article in the August 2020 issue of IJGC. Dr. Nasioudis is a resident at the Hospital of the University of Pennsylvania, Philadelphia. His current interests include population science and outcomes research with an emphasis on rare gynecologic tumors.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Ainhoa Madariaga to discuss parp inhibitor treatments and adverse events. Dr. Madariaga's article, "Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events," (https://ijgc.bmj.com/content/early/2020/06/08/ijgc-2020-001288) is the Lead Article in the July 2020 issue of IJGC. Dr. Madariaga is a medical oncologist working as a clinical research fellow in the gynecology and drug development program at Princess Margaret Cancer Centre. Her clinical and academic areas of interest are gynecologic cancers and early phase clinical trial design; such as development of drug-repurposing studies, cancer treatment adverse event and patient reported outcomes assessment.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Yan Xiaojian to discuss open vs. MIS radical hysterectomy

Workers' Liberty Vol. 3, issue 68 Hear the appendices: https://soundcloud.com/workers-liberty/morality-revolution-the-bolsheviks-and-us-22-appendices Issue online: https://www.workersliberty.org/publications/workers-liberty-magazine/latest-issue/workers-liberty-volume-3-september-2005/morality Article online: https://www.workersliberty.org/story/2019-06-07/morality-revolution-bolsheviks-and-us

Solidarity 531/Workers' Liberty 70 — Automation and the working class. Lead article, Automation and the working class, by Martin Thomas. Article at: https://workersliberty.org/story/2020-01-14/automation-and-working-class See also: https://soundcloud.com/workers-liberty/automation-2-the-future-and-robots-hipster-reformism-and-the-technological-fix https://soundcloud.com/workers-liberty/automation-4-marxs-telescope https://soundcloud.com/workers-liberty/automation-5-the-great-foundation-stone-of-wealth Full pamphlet at: https://workersliberty.org/WL70 Browse and subscribe to all audio: https://workersliberty.org/audio

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Tien Le to discuss comparison of oncologic outcomes in endometrial cancer: robotics vs. laparotomy, especially in regards to his article, “A comparison of disease recurrence between robotic versus laparotomy approach in patients with intermediate-risk endometrial cancer,” which is the Lead Article in IJGC’s February 2020 issue. Dr. Le is currently a Full Professor and the Gynecologic Oncology Fellowship program director in the Division of Gynecologic Oncology at the University of Ottawa. He has special interests in health service evaluations research and minimal invasive surgery.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. David Cibula to discuss the ESGO Cervical Cancer Quality Indicators, which features as the Lead Article in the January 2020 issue of IJGC (https://ijgc.bmj.com/content/30/1/3). Dr. Cibula is the Chair of the Gynecologic Oncology Center at the General Faculty Hospital in Prague, Chair of the Central and Eastern European Gynaecologic Oncology Group (CEEGOG), as well as a Former ESGO president.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Walter Gotlieb to talk about robotic surgery for interval cytoreduction in advanced ovarian cancer and his article, "Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy" (https://ijgc.bmj.com/content/early/2019/10/09/ijgc-2019-000413), which is the Lead Article for the November 2019 issue of the International Journal of Gynecological Cancer. Dr. Gotlieb is Professor & Chief of ObGyn at the McGill-affiliated Jewish General Hospital in Montreal. He is past President of GOC, the Gyn-Onc Society of Canada, past Secretary Treasurer of IGCS, and completed 10 years as senior editor of the IJGC.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Ester Miralpeix from Hospital Del Mar to talk about prehabilitation programs in gynecologic oncology and her article, ""Role and impact of multimodal prehabilitation for gynecologic oncology patients in an Enhanced Recovery After Surgery (ERAS) program"" {https://ijgc.bmj.com/content/early/2019/08/30/ijgc-2019-000597), which is the Lead Article for the November 2019 issue of IJGC. Dr. Ester Miralpeix is currently working at Hospital del Mar, Barcelona as a gynecologist and as an Associate Professor at Universitat Autònoma de Barcelona. During her career, she has rotated in some leading cancer centers like University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center. Dr. Miralpeiz has always been heavily involved in gynecologic cancer and the development of innovative strategies for improving patient care trough ERAS and Prehabilitation programs."

In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Dr. Christhardt Köhler from Asklepios Clinic Hamburg-Altona to talk about his article “Laparoscopic radical hysterectomy with transvaginal closure of vaginal cuff – a multicenter analysis," which is the Lead Article for the June issue.

In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Dr. Patrice Mathevet from the University of Lausanne in Switzerland. Dr. Mathevet is the author of the Lead Article for the March 2019 issue, "Impact of micrometastasis or isolated tumor cells on recurrence and survival in patients with early cervical cancer: SENTICOL Trial." They discuss the aim and results of the study, as well as the implications for future treatment.

In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Dr. Juan Luis Alcázar (Twitter: @Juan_L_Alcazar) from the Department of Obstetrics and Gynecology, Clínica Universidad de Navarra in Pamplona, Spain. Dr. Alcázar is the lead author of the Lead Article for the February 2019 issue, "Preoperative assessment of intra-abdominal disease spread in epithelial ovarian cancer: a comparative study between ultrasound and computed tomography scan." They discuss the rationale behind the study, the advantages and limitations of using ultrasound, the recent evolution of ultrasound technology, and recommendations for centers that may be lacking an expert ultrasonographer.

In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Dr. Anna Fagotti (Twitter: @annafagottimd) from Policlinico Universitario Agostino Gemelli in Rome. Dr. Fagotti is the lead author of the Lead Article for the February 2018 issue, "The INTERNATIONAL MISSION study: Minimally Invasive Surgery In Ovarian Neoplasms after NACT." They discuss the origins and results of the study, what makes a patient an ideal candidate for minimally invasive surgery, and the next steps for evaluating oncologic outcomes.

Brous is a nurse and attorney, a contributing editor for AJN, and coordinates our legal column. AJN editor-in-chief discusses with Brous common problems that lead nurses to her door and what nurses can learn from this particular case.

Podcast discussion with Eric Barreto, Cameron Howard, and James Boyce. Article written by James Boyce. Where did the Bible come from? For most Christians questions about the origins of the Bible are not just a matter of idle curiosity. Virtually all of us hold these writings we call the Scriptures as read more...